High	0	4	O
-	4	5	O
Dose	5	9	O
celecoxib	10	19	B-Drug_or_compound
and	20	23	O
metronomic	24	34	O
"	35	36	O
low	36	39	O
-	39	40	O
dose	40	44	O
"	44	45	O
cyclophosphamide	46	62	B-Drug_or_compound
is	63	65	O
an	66	68	O
effective	69	78	O
and	79	82	O
safe	83	87	O
therapy	88	95	O
in	96	98	O
patients	99	107	B-Organism
with	108	112	O
relapsed	113	121	O
and	122	125	O
refractory	126	136	O
aggressive	137	147	O
histology	148	157	O
non	158	161	B-Pathological_formation
-	161	162	I-Pathological_formation
Hodgkin	162	169	I-Pathological_formation
'	169	170	I-Pathological_formation
s	170	171	I-Pathological_formation
lymphoma	172	180	I-Pathological_formation
.	180	181	O

PURPOSE	183	190	O
:	190	191	O
Angiogenesis	192	204	O
is	205	207	O
increased	208	217	O
in	218	220	O
aggressive	221	231	O
histology	232	241	O
non	242	245	B-Pathological_formation
-	245	246	I-Pathological_formation
Hodgkin	246	253	I-Pathological_formation
'	253	254	I-Pathological_formation
s	254	255	I-Pathological_formation
lymphoma	256	264	I-Pathological_formation
and	265	268	O
may	269	272	O
be	273	275	O
a	276	277	O
target	278	284	O
with	285	289	O
selective	290	299	O
cyclooxygenase	300	314	B-Drug_or_compound
-	314	315	I-Drug_or_compound
2	315	316	I-Drug_or_compound
inhibition	317	327	O
and	328	331	O
metronomic	332	342	O
chemotherapy	343	355	O
.	355	356	O

EXPERIMENTAL	357	369	O
DESIGN	370	376	O
:	376	377	O
We	378	380	O
assessed	381	389	O
response	390	398	O
,	398	399	O
toxicity	400	408	O
,	408	409	O
and	410	413	O
biomarkers	414	424	O
of	425	427	O
angiogenesis	428	440	O
to	441	443	O
low	444	447	O
-	447	448	O
dose	448	452	O
cyclophosphamide	453	469	B-Drug_or_compound
(	470	471	O
50	471	473	O
mg	474	476	O
p	477	478	O
.	478	479	O
o	479	480	O
.	480	481	O
o	482	483	O
.	483	484	O
d	484	485	O
.	485	486	O
)	486	487	O
and	488	491	O
high	492	496	O
-	496	497	O
dose	497	501	O
celecoxib	502	511	B-Drug_or_compound
(	512	513	O
400	513	516	O
mg	517	519	O
p	520	521	O
.	521	522	O
o	522	523	O
.	523	524	O
b	525	526	O
.	526	527	O
i	527	528	O
.	528	529	O
d	529	530	O
.	530	531	O
)	531	532	O
in	533	535	O
adult	536	541	O
patients	542	550	B-Organism
with	551	555	O
relapsed	556	564	O
or	565	567	O
refractory	568	578	O
aggressive	579	589	O
non	590	593	B-Pathological_formation
-	593	594	I-Pathological_formation
Hodgkin	594	601	I-Pathological_formation
'	601	602	I-Pathological_formation
s	602	603	I-Pathological_formation
lymphoma	604	612	I-Pathological_formation
in	613	615	O
a	616	617	O
multicenter	618	629	O
phase	630	635	O
II	636	638	O
prospective	639	650	O
study	651	656	O
.	656	657	O

RESULTS	658	665	O
:	665	666	O
Thirty	667	673	O
-	673	674	O
two	674	677	O
of	678	680	O
35	681	683	O
patients	684	692	B-Organism
(	693	694	O
median	694	700	O
age	701	704	O
,	704	705	O
62	706	708	O
years	709	714	O
)	714	715	O
are	716	719	O
evaluable	720	729	O
for	730	733	O
response	734	742	O
.	742	743	O

Patients	744	752	B-Organism
had	753	756	O
primarily	757	766	O
relapsed	767	775	O
diffuse	776	783	O
large	784	789	O
B	790	791	B-Pathological_formation
-	791	792	I-Pathological_formation
cell	792	796	I-Pathological_formation
lymphoma	797	805	I-Pathological_formation
(	806	807	O
63	807	809	O
%	809	810	O
)	810	811	O
were	812	816	O
heavily	817	824	O
pretreated	825	835	O
(	836	837	O
median	837	843	O
of	844	846	O
three	847	852	O
regimens	853	861	O
)	861	862	O
and	863	866	O
high	867	871	O
risk	872	876	O
(	877	878	O
79	878	880	O
%	880	881	O
international	882	895	O
prognostic	896	906	O
index	907	912	O
,	912	913	O
greater	915	922	O
than	923	927	O
or	928	930	O
=	930	931	O
2	931	932	O
)	932	933	O
and	934	937	O
34	938	940	O
%	940	941	O
were	942	946	O
relapsed	947	955	O
after	956	961	O
autologous	962	972	O
stem	973	977	B-Cell
cell	978	982	I-Cell
transplant	983	993	O
.	993	994	O

With	995	999	O
a	1000	1001	O
median	1002	1008	O
follow	1009	1015	O
-	1015	1016	O
up	1016	1018	O
of	1019	1021	O
8	1022	1023	O
.	1023	1024	O
4	1024	1025	O
months	1026	1032	O
,	1032	1033	O
the	1034	1037	O
overall	1038	1045	O
best	1046	1050	O
response	1051	1059	O
rate	1060	1064	O
is	1065	1067	O
37	1068	1070	O
%	1070	1071	O
(	1072	1073	O
2	1073	1074	O
complete	1075	1083	O
clinical	1084	1092	O
response	1093	1101	O
/	1101	1102	O
complete	1102	1110	O
clinical	1111	1119	O
response	1120	1128	O
unconfirmed	1129	1140	O
and	1141	1144	O
9	1145	1146	O
partial	1147	1154	O
response	1155	1163	O
)	1163	1164	O
,	1164	1165	O
with	1166	1170	O
22	1171	1173	O
%	1173	1174	O
achieving	1175	1184	O
stable	1185	1191	O
disease	1192	1199	O
.	1199	1200	O

Median	1201	1207	O
overall	1208	1215	O
and	1216	1219	O
progression	1220	1231	O
-	1231	1232	O
free	1232	1236	O
survivals	1237	1246	O
are	1247	1250	O
14	1251	1253	O
.	1253	1254	O
4	1254	1255	O
and	1256	1259	O
4	1260	1261	O
.	1261	1262	O
7	1262	1263	O
months	1264	1270	O
,	1270	1271	O
respectively	1272	1284	O
.	1284	1285	O

The	1286	1289	O
median	1290	1296	O
response	1297	1305	O
duration	1306	1314	O
was	1315	1318	O
8	1319	1320	O
.	1320	1321	O
2	1321	1322	O
months	1323	1329	O
.	1329	1330	O

The	1331	1334	O
most	1335	1339	O
common	1340	1346	O
toxicity	1347	1355	O
was	1356	1359	O
skin	1360	1364	B-Organ
rash	1365	1369	O
(	1370	1371	O
40	1371	1373	O
%	1373	1374	O
)	1374	1375	O
;	1375	1376	O
myelosuppression	1377	1393	O
and	1394	1397	O
gastrointestinal	1398	1414	B-Organism_subdivision
side	1415	1419	O
effects	1420	1427	O
were	1428	1432	O
uncommon	1433	1441	O
.	1441	1442	O

Three	1443	1448	O
patients	1449	1457	B-Organism
developed	1458	1467	O
deep	1468	1472	B-Pathological_formation
vein	1473	1477	I-Pathological_formation
thromboses	1478	1488	I-Pathological_formation
and	1489	1492	O
two	1493	1496	O
heavily	1497	1504	O
pretreated	1505	1515	O
patients	1516	1524	B-Organism
developed	1525	1534	O
treatment	1535	1544	O
-	1544	1545	O
related	1545	1552	O
acute	1553	1558	O
myelogenous	1559	1570	O
leukemia	1571	1579	O
or	1580	1582	O
myelodysplasia	1583	1597	O
after	1598	1603	O
3	1604	1605	O
.	1605	1606	O
7	1606	1607	O
and	1608	1611	O
12	1612	1614	O
months	1615	1621	O
of	1622	1624	O
therapy	1625	1632	O
.	1632	1633	O

Circulating	1634	1645	O
endothelial	1646	1657	B-Cell
cells	1658	1663	I-Cell
and	1664	1667	O
their	1668	1673	O
precursors	1674	1684	O
declined	1685	1693	O
and	1694	1697	O
remained	1698	1706	O
low	1707	1710	O
in	1711	1713	O
responders	1714	1724	O
,	1724	1725	O
whereas	1726	1733	O
plasma	1734	1740	B-Organism_substance
vascular	1741	1749	B-Gene_or_gene_product
endothelial	1750	1761	I-Gene_or_gene_product
growth	1762	1768	I-Gene_or_gene_product
factor	1769	1775	I-Gene_or_gene_product
trended	1776	1783	O
to	1784	1786	O
decline	1787	1794	O
in	1795	1797	O
responding	1798	1808	O
patients	1809	1817	B-Organism
but	1818	1821	O
increase	1822	1830	O
in	1831	1833	O
nonresponders	1834	1847	O
.	1847	1848	O

Trough	1849	1855	O
celecoxib	1856	1865	B-Drug_or_compound
levels	1866	1872	O
achieved	1873	1881	O
targeted	1882	1890	O
"	1891	1892	O
antiangiogenic	1892	1906	O
"	1906	1907	O
levels	1908	1914	O
.	1914	1915	O

CONCLUSIONS	1916	1927	O
:	1927	1928	O
Low	1929	1932	O
-	1932	1933	O
dose	1933	1937	O
cyclophosphamide	1938	1954	B-Drug_or_compound
and	1955	1958	O
high	1959	1963	O
-	1963	1964	O
dose	1964	1968	O
celecoxib	1969	1978	B-Drug_or_compound
is	1979	1981	O
well	1982	1986	O
tolerated	1987	1996	O
and	1997	2000	O
active	2001	2007	O
in	2008	2010	O
pretreated	2011	2021	O
aggressive	2022	2032	O
non	2033	2036	B-Pathological_formation
-	2036	2037	I-Pathological_formation
Hodgkin	2037	2044	I-Pathological_formation
'	2044	2045	I-Pathological_formation
s	2045	2046	I-Pathological_formation
lymphoma	2047	2055	I-Pathological_formation
.	2055	2056	O

Close	2057	2062	O
surveillance	2063	2075	O
for	2076	2079	O
arterial	2080	2088	O
and	2089	2092	O
venous	2093	2099	O
thrombotic	2100	2110	O
events	2111	2117	O
is	2118	2120	O
recommended	2121	2132	O
.	2132	2133	O

The	2134	2137	O
decline	2138	2145	O
in	2146	2148	O
circulating	2149	2160	O
endothelial	2161	2172	B-Cell
cells	2173	2178	I-Cell
and	2179	2182	O
their	2183	2188	O
precursors	2189	2199	O
suggests	2200	2208	O
that	2209	2213	O
this	2214	2218	O
combination	2219	2230	O
may	2231	2234	O
be	2235	2237	O
working	2238	2245	O
by	2246	2248	O
inhibiting	2249	2259	O
angiogenesis	2260	2272	O
but	2273	2276	O
should	2277	2283	O
be	2284	2286	O
validated	2287	2296	O
in	2297	2299	O
a	2300	2301	O
larger	2302	2308	O
patient	2309	2316	B-Organism
sample	2317	2323	O
.	2323	2324	O

